Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01452061|
Recruitment Status : Completed
First Posted : October 14, 2011
Last Update Posted : January 29, 2014
There are three purposes to this study. The first purpose is to evaluate the value of a genetic test in determining risk for autism spectrum disorder. Processing for genetic samples will be completed at the Cleveland Clinic using research equipment provided by IntegraGen. The second purpose is to identify genetic changes that may be associated with autism spectrum disorder or attention deficit/hyperactivity disorder. The third purpose is to examine whether genetic differences and changes may predict which individuals benefit from medicine used to treat attention problems or other psychiatric difficulties.
Between 600-800 people are expected to participate in this study - approximately 300 individuals with an autism spectrum disorder, 75 individuals with attention deficit/hyperactivity disorder or another developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals without a developmental or psychiatric disorder.
Study procedures will vary based upon the specific group participants are suspected to fall into (autism, attention deficit/hyperactivity disorder, psychiatric concerns/developmental delay, healthy sibling, or unrelated healthy control).
- All individuals will be asked to participate in a cheek swab (gently swabbing the inside of your cheek) to obtain cells used for genetic testing. Genetic material will be stored with identifiers such as numbers, letters or codes.
- Parents or caregivers will be asked to complete questionnaires that examine medical and family history as well as current symptoms and quality of life for the participant.
- Participants may undergo speech and language testing. This involves answering questions, looking at pictures or identifying items.
- Information recorded in participant medical records will be reviewed and collected for this study.
|Condition or disease|
|Autism Spectrum Disorder Attention Deficit/Hyperactivity Disorder Developmental Delay|
|Study Type :||Observational|
|Actual Enrollment :||456 participants|
|Observational Model:||Case Control|
|Official Title:||Understanding Genetic Differences Associated With Autism Spectrum and Attention Deficit/Hyperactivity Disorder|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Participants with autism spectrum disorder.
Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
Siblings without a developmental or psychiatric disorder.
Unrelated individuals without a developmental or psychiatric disorder.
- Autism Spectrum Disorder clinical diagnosis [ Time Frame: March 2014 ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01452061
|United States, Ohio|
|Cleveland Clinic Center for Autism|
|Cleveland, Ohio, United States, 44104|
|Principal Investigator:||Thomas W Frazier, Ph.D.||The Cleveland Clinic|
|Principal Investigator:||Charis Eng, M.D., Ph.D.||The Cleveland Clinic|